Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide

Table 2

Treatment characteristics and clinical outcomes.

Characteristic	All patients; ()	L-SII; ()	H-SII; ()	value
RT technique, (%)
3D-CRT	93 (55.7)	45 (56.3)	48 (55.2)	0.79
SIB-IMRT	74 (44.3)	35 (43.7)	39 (44.8)
RT dose, (%)
60 Gy	86 (51.5)	42 (52.5)	44 (50.6)	0.62
70 Gy	81 (48.5)	38 (47.5)	43 (49.4)
Adjuvant TMZ cycles, (%)
1-5	48 (28.8)	23 (28.8)	25 (28.7)	0.96
6-12	119 (71.2)	57 (71.2)	62 (71.3)
Brain failure, (%)
None	11 (6.6)	3 (3.8)	8 (9.2)	0.53
Infield	129 (77.3)	63 (78.8)	66 (75.9)
Marginal	16 (9.6)	9 (11.2)	7 (8.0)
Distant	6 (3.5)	2 (2.5)	4 (4.5)
Infield and distant	3 (1.8)	2 (2.5)	1 (1.2)
Marginal and distant	2 (1.2)	1 (1.2)	1 (1.2)
Salvage treatment, (%)
None	76 (45.5)	36 (45.0)	40 (46.0)	0.54
Unknown	6 (3.6)	4 (5.0)	2 (2.4)
SNS alone	17 (10.2)	8 (10.0)	9 (10.4)
SRS/SRT	14 (8.4)	7 (8.7)	7 (7.9)
SNS+SRS/SRT	8 (4.8)	3 (3.8)	5 (5.8)
SNS+Ctx	15 (9.0)	8 (10.0)	7 (7.9)
SNS+SRS+Ctx	7 (4.2)	3 (3.8)	4 (4.7)
Ctx alone	24 (14.3)	11 (13.7)	13 (14.9)
PFS
Median, mo (95% CI)	9.0 (7.0-11.0)	16.6 (13.8-19.4)	6.0 (3.1-8.9)	<0.001
3 years (%)	11.9	21.4	2.8
5 years (%)	6.6	13.4	0
OS
Median, mo (95% CI)	14.4 (11.9-16.9)	22.9 (18.8-27.0)	11.1 (8.4-13.9)	<0.001
3 years, %	14.0	23.0	4.7
5 years, %	9.8	18.9	0

L-SII: low systemic immune-inflammation index; H-SII: high-SII; RT: radiotherapy; TMZ: temozolomide; SNS: salvage neurosurgery; SRS: stereotactic radiosurgery; SRT: stereotactic radiotherapy; Ctx: chemotherapy; PFS: progression-free survival; OS: overall survival; CI: confidence interval.